Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- MONDO_0005391 label "restless leg syndrome" assertion.
- context label "Adults" assertion.
- association label "It also has off label use as monotherapy or adjunctive therapy for the treatment of mania, restless leg syndrome, insomnia, tardive dyskinesia, and REM sleep behavior disorder." assertion.
- context label "Adults" assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- context label "Adults" assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- context label "Adults" assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- context label "Adults" assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- context label "Adults" assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- context label "Adults" assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- context label "Adults" assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- context label "Adults" assertion.
- association label "Off-label use includes treatment of cholestatic pruritus in adults." assertion.
- HP_000098 label "pruritus" assertion.
- context label "Adults" assertion.
- association label "Sedating antidepressants (e.g., amitriptyline, trazodone, mirtazapine) are often prescribed off-label as sleeping aids" assertion.
- context label "Adults" assertion.
- association label "Sedating antidepressants (e.g., amitriptyline, trazodone, mirtazapine) are often prescribed off-label as sleeping aids" assertion.
- context label "Children and adolescents" assertion.
- association label "Melatonin (97%), trazodone (81%), and quetiapine (73%) were rated by a majority of respondents as effective. Doxepin, zaleplon, tricyclic antidepressants, zolpidem, or lorazepam were rarely prescribed due to lack of evidence and/or concerns about adverse effects, long-term safety, suitability for youth, suicidality, and dependence/tolerance." assertion.
- context label "Children and adolescents" assertion.
- association label "Melatonin (97%), trazodone (81%), and quetiapine (73%) were rated by a majority of respondents as effective. Doxepin, zaleplon, tricyclic antidepressants, zolpidem, or lorazepam were rarely prescribed due to lack of evidence and/or concerns about adverse effects, long-term safety, suitability for youth, suicidality, and dependence/tolerance." assertion.
- context label "Children and adolescents" assertion.
- association label "Melatonin (97%), trazodone (81%), and quetiapine (73%) were rated by a majority of respondents as effective. Doxepin, zaleplon, tricyclic antidepressants, zolpidem, or lorazepam were rarely prescribed due to lack of evidence and/or concerns about adverse effects, long-term safety, suitability for youth, suicidality, and dependence/tolerance." assertion.
- context label "Children and adolescents" assertion.
- association label "Melatonin (97%), trazodone (81%), and quetiapine (73%) were rated by a majority of respondents as effective. Doxepin, zaleplon, tricyclic antidepressants, zolpidem, or lorazepam were rarely prescribed due to lack of evidence and/or concerns about adverse effects, long-term safety, suitability for youth, suicidality, and dependence/tolerance." assertion.
- DB00962 label "Zaleplon" assertion.
- context label "Children and adolescents" assertion.
- association label "Melatonin (97%), trazodone (81%), and quetiapine (73%) were rated by a majority of respondents as effective. Doxepin, zaleplon, tricyclic antidepressants, zolpidem, or lorazepam were rarely prescribed due to lack of evidence and/or concerns about adverse effects, long-term safety, suitability for youth, suicidality, and dependence/tolerance." assertion.
- context label "Children and adolescents" assertion.
- association label "Melatonin (97%), trazodone (81%), and quetiapine (73%) were rated by a majority of respondents as effective. Doxepin, zaleplon, tricyclic antidepressants, zolpidem, or lorazepam were rarely prescribed due to lack of evidence and/or concerns about adverse effects, long-term safety, suitability for youth, suicidality, and dependence/tolerance." assertion.
- context label "adults" assertion.
- association label "Off-label use of (R,S)-ketamine, which is an equal mixture of (R)-ketamine and (S)-ketamine, has become especially popular in the United States (US) for treatment-resistant depression." assertion.
- context label "adults" assertion.
- association label "Antidepressants (eg, tricyclic antidepressants [TCAs], SNRIs, SSRIs) are often prescribed off label to manage cataplexy" assertion.
- context label "adults" assertion.
- association label "Antidepressants (eg, tricyclic antidepressants [TCAs], SNRIs, SSRIs) are often prescribed off label to manage cataplexy" assertion.
- context label "adults" assertion.
- association label "Antidepressants (eg, tricyclic antidepressants [TCAs], SNRIs, SSRIs) are often prescribed off label to manage cataplexy" assertion.
- DB00234 label "Reboxetine" assertion.
- context label "adults" assertion.
- association label "Antidepressants (eg, tricyclic antidepressants [TCAs], SNRIs, SSRIs) are often prescribed off label to manage cataplexy" assertion.
- context label "adults" assertion.
- association label "Several controlled trials have demonstrated the rapid effects of intravenous ketamine. As a result, the use of this off-label treatment has grown exponentially in recent years." assertion.
- context label "Adults" assertion.
- association label "Strong evidence supports the rapid, although temporary, antidepressant effects of a single intravenous ketamine infusion for treatment-resistant major depressive disorder (MDD) and bipolar depression." assertion.
- context label "Adults" assertion.
- association label "Strong evidence supports the rapid, although temporary, antidepressant effects of a single intravenous ketamine infusion for treatment-resistant major depressive disorder (MDD) and bipolar depression." assertion.
- context label "adults" assertion.
- association label "Other off-label therapies that have been used to treat HSDD include transdermal testosterone for peri- and post-menopausal women, and oral bupropion and buspirone" assertion.
- context label "adults" assertion.
- association label "Other off-label therapies that have been used to treat HSDD include transdermal testosterone for peri- and post-menopausal women, and oral bupropion and buspirone" assertion.
- context label "adults" assertion.
- association label "While ketamine has not been approved for depression in the USA or in any other country, it has been used off-label in cases of severe depression." assertion.
- context label "adults" assertion.
- association label "In patients with Li-NDI, off label therapy with amiloride can be useful." assertion.
- context label "adults" assertion.
- association label "TCAs have been shown to be effective for managing and preventing chronic headache syndromes.3,4" assertion.
- context label "adults" assertion.
- association label "TCAs have been used to treat chronic low back pain for decades and have been repeatedly shown to be more effective than placebo in reducing pain severity" assertion.
- context label "adults" assertion.
- association label "TCAs can serve as first-line or augmenting drugs for neuropathic pain, headache, migraine, gastrointestinal syndromes, fibromyalgia, pelvic pain, insomnia, and psychiatric conditions other than depression." assertion.
- context label "adults" assertion.
- association label "Patients with irritable bowel syndrome have long been known to benefit from TCAs; the number needed to treat for symptomatic benefit over placebo is 3.5" assertion.
- context label "adults" assertion.
- association label "TCAs can serve as first-line or augmenting drugs for neuropathic pain, headache, migraine, gastrointestinal syndromes, fibromyalgia, pelvic pain, insomnia, and psychiatric conditions other than depression." assertion.
- context label "adults" assertion.
- association label "TCAs can serve as first-line or augmenting drugs for neuropathic pain, headache, migraine, gastrointestinal syndromes, fibromyalgia, pelvic pain, insomnia, and psychiatric conditions other than depression." assertion.
- context label "adults" assertion.
- association label "TCAs have also shown prophylactic benefit in cyclic vomiting syndrome, with a clinical response in over 75% of patients in controlled cohort studies." assertion.
- context label "adults" assertion.
- association label "Information extracted from Table 2." assertion.
- context label "adults" assertion.
- association label "TCAs can serve as first-line or augmenting drugs for neuropathic pain, headache, migraine, gastrointestinal syndromes, fibromyalgia, pelvic pain, insomnia, and psychiatric conditions other than depression." assertion.
- context label "Children" assertion.
- association label "However, there are no sleep medications approved by the United States Food and Drug Administration and only one has been approved by the European Medicines Agency for pediatric insomnia; thus, most medications are prescribed off-label. Melatonin is widely used and safe in children with neurodevelopmental conditions. Gabapentin, clonidine, trazodone, and mirtazapine hold promise but require further study." assertion.
- context label "Children" assertion.
- association label "However, there are no sleep medications approved by the United States Food and Drug Administration and only one has been approved by the European Medicines Agency for pediatric insomnia; thus, most medications are prescribed off-label. Melatonin is widely used and safe in children with neurodevelopmental conditions. Gabapentin, clonidine, trazodone, and mirtazapine hold promise but require further study." assertion.
- context label "Adults" assertion.
- association label "Antidepressants, particularly TCAs and SNRIs, have also found their application in relieving pain related with fibromyalgia. Table 2 contains off-label drugs prescribed." assertion.
- context label "Adults" assertion.
- association label "Antidepressants, particularly TCAs and SNRIs, have also found their application in relieving pain related with fibromyalgia" assertion.
- context label "Adults" assertion.
- association label "Antidepressants, particularly TCAs and SNRIs, have also found their application in relieving pain related with fibromyalgia" assertion.
- context label "Adults" assertion.
- association label "Antidepressants, particularly TCAs and SNRIs, have also found their application in relieving pain related with fibromyalgia" assertion.
- context label "Adults" assertion.
- association label "nan" assertion.
- context label "Adults" assertion.
- association label "nan" assertion.
- context label "Adults" assertion.
- association label "The observed efficacy of antidepressants as treatment for bulimia nervosa led to trials to evaluate their effect on binge eating disorder. Antidepressants that have shown promising results include bupropion, duloxetine, escitalopram, fluvoxamine, fluoxetine, imipramine, sertraline and venlafaxine" assertion.
- context label "Adults" assertion.
- association label "The observed efficacy of antidepressants as treatment for bulimia nervosa led to trials to evaluate their effect on binge eating disorder. Antidepressants that have shown promising results include bupropion, duloxetine, escitalopram, fluvoxamine, fluoxetine, imipramine, sertraline and venlafaxine" assertion.